The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration
Abstract
PURPOSE: To develop a pretreatment prognostic model for survival of patients with progressive metastatic prostate cancer after castration using parameters that are measured during routine clinical management. PATIENTS AND METHODS: Pretreatment clinical and biochemical determinants from 409 patients enrolled onto 19 consecutive therapeutic protocols from June 1989 through January 2000 were evaluated. The factors selected were age, Karnofsky performance status (KPS), hemoglobin (HGB), prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (ALK), and albumin. These factors were combined in an accelerated failure time regression model to produce a nomogram to predict median, 1-year, and 2-year survival. The nomogram was validated internally and externally using data from a multicenter randomized trial of suramin plus hydrocortisone versus hydrocortisone alone. RESULTS: The median survival of the entire group was 15.8 months (range, 0.9 to 77.8 months); 87% have died. In multivariable analysis, KPS, HGB, ALK, albumin, and LDH were significantly associated with survival (P < .05), whereas age and PSA were not. All seven factors were included in the nomogram. When applied to the external validation data set, the nomogram achieved a concordance index of 0.67. Calibration plots suggested that the nomogram was well calibrated for all predictions. CONCLUSION: A nomogram derived from pretreatment parameters that are measured on a routine basis was constructed. It can be used to predict the median, 1-year, and 2-year survival of patients with progressive castrate metastatic disease with reasonable accuracy. The information is useful to assess prognosis, guide treatment selection, and design clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Relationship between cancer patients' predictions of prognosis and their treatment preferences
Weeks, J. C. (1998) · JAMA · doi:10.1001/jama.279.21.1709 · Cited by 1,319
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Self-citationKantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Soloway, M. S., Hardeman, S. W., Hickey, D., Todd, B., Soloway, S., Raymond, J., & Moinuddin, M. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y · Cited by 631
Tu, S.-M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C., Daliani, D., Papandreou, C. N., Smith, T. L., Kim, J., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03639-4 · Cited by 396
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
Self-citationMazumdar, M., & Glassman, J. R. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000115)19:1<113::aid-sim245>3.0.co;2-o · Cited by 367
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 351
Savarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M.-E., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 323
Self-citationPhase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Judge, T. W., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D. F., Fine, R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.958 · Cited by 311
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., & Friedman, M. A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.827 · Cited by 267
Sabbatini, P., Larson, S. M., Kremer, A., Zhang, Z.-F., Sun, M., Yeung, H., Imbriaco, M., Horak, I., Conolly, M., Ding, C., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.948 · Cited by 237
Self-citationClinical states in prostate cancer: toward a dynamic model of disease progression
Scher, H. I., & Heller, G. (2000) · Urology · doi:10.1016/s0090-4295(99)00471-9 · Cited by 232
Self-citationBicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., & Schwartz, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2928 · Cited by 227
Self-citationSmith, D. C., Dunn, R. L., Strawderman, M. S., & Pienta, K. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1835 · Cited by 215
Antiangiogenic Activity of Prostate-Specific Antigen
Fortier, A. H., Nelson, B. J., Grella, D. K., & Holaday, J. W. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1635 · Cited by 210
Small, E. J., Meyer, M., Marshall, M. E., Reyno, L. M., Meyers, F. J., Natale, R. B., Lenehan, P. F., Chen, L., Slichenmyer, W. J., & Eisenberger, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1440 · Cited by 186
Self-citationPaclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer
Kelly, W. K., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D., Ciolino, A., Regan, K., Schwartz, M., Kantoff, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.44 · Cited by 182
Self-citationScher, H. I., Kelly, W. M. K., Zhang, Z.-F., Ouyang, P., Sun, M., Schwartz, M., Ding, C., Wang, W., Horak, I. D., & Kremer, A. B. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.244 · Cited by 165
Self-citationMorris, M. J., Tong, W. P., Cordon‐Cardo, C., Drobnjak, M., Kelly, W. K., Slovin, S. F., Terry, K. L., Siedlecki, K. L., Swanson, P. M., Rafi, M., et al. (2002) · PubMed · Cited by 161
Self-citationHussain, M., Wolf, M., Marshall, E., Crawford, E. D., & Eisenberger, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1868 · Cited by 158
HER‐2 profiling and targeting in prostate carcinoma
Morris, M. J., Reuter, V. E., Kelly, W. K., Slovin, S. F., Kenneson, K., Verbel, D., Osman, I., & Scher, H. I. (2002) · Cancer · doi:10.1002/cncr.10339 · Cited by 138
Self-citationSmall, E. J., McMillan, A., Meyer, M., Chen, L., Slichenmyer, W. J., Lenehan, P. F., & Eisenberger, M. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1304 · Cited by 83
Self-citationUSING FULL PROBABILITY MODELS TO COMPUTE PROBABILITIES OF ACTUAL INTEREST TO DECISION MAKERS
Harrell, F. E., & Shih, Y. T. (2001) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462301104034 · Cited by 72
Use of adaptive control with feedback to individualize suramin dosing.
Scher, H. I., Jodrell, D. I., Iversen, J. M., Curley, T., Tong, W. P., Egorin, M. J., & Forrest, A. (1992) · PubMed · Cited by 58
Self-citationKelly, W. K., Osman, I., Reuter, V. E., Curley, T., Heston, W. D. W., Nanus, D. M., & Scher, H. I. (2000) · PubMed · Cited by 57
Self-citationPetylak, D. P., Scher, H. I., Li, Z., Myers, C. E., & Geller, N. L. (1992) · Cancer · doi:10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f · Cited by 51
Self-citationSchultz, P., Kelly, W. K., Begg, C. B., Liebertz, C., Cohen, L., & Scher, H. I. (1994) · Urology · doi:10.1016/s0090-4295(94)80138-x · Cited by 8
Self-citationStage as major long term outcome predictor in minor salivary gland carcinoma
Lutgendorf (2000) · Pure Amsterdam UMC · doi:10.1002/1097-0142(20000915)89:6 · Cited by 1
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Harrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationSmall, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Self-citation
Metadata
- Authors
- Smaletz, O., Scher, H. I., Small, E. J., Verbel, D. A., McMillan, A., Regan, K., Kelly, W. K., & Kattan, M. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-10-01
- Volume
- 20
- Issue
- 19
- Pages
- 3972-3982
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167869791
- Cited by
- 386
- References
- 36
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.